Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Clearance marks major shift beyond chemotherapy
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The development comes as stroke remains one of the world’s biggest health threats
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Baxfendy works in a fundamentally different way from current therapies
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Subscribe To Our Newsletter & Stay Updated
